Array Biopharma (ARRY) Tops Q1 EPS by 10c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.90 -7.49%
Revenue Growth %: -11.6%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -11.6%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.12), $0.10 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $56.9 million versus the consensus estimate of $34.5 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
